Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.60 |
| ▸ | TGM2 | P21980 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553844 | 0.91 | MEN1 (0.60) | ALDH1A1LMNACYP19A1TGM2MEN1 | |
| SCHEMBL4735984 | 0.88 | ALDH1A1 (0.65) | ALDH1A1LMNACYP19A1TGM2MEN1 | |
| SCHEMBL553235 | 0.87 | TGM2 (0.54) | ALDH1A1LMNACYP19A1TGM2MEN1 | |
| SCHEMBL17336919 | 0.87 | NOTUM (0.58) | ALDH1A1LMNACYP19A1TGM2MEN1 | |
| SCHEMBL9857993 | 0.87 | ALDH1A1 (0.63) | ALDH1A1LMNACYP19A1TGM2MEN1 | |
| SCHEMBL14706717 | 0.87 | ALDH1A1 (0.68) | ALDH1A1LMNACYP19A1TGM2MEN1 | |
| SCHEMBL10660863 | 0.87 | TYR (0.54) | ALDH1A1LMNACYP19A1TGM2HDAC1 | |
| SCHEMBL17336928 | 0.85 | NPC1 (0.60) | ALDH1A1LMNACYP19A1TGM2MEN1 | |
| SCHEMBL17336894 | 0.85 | TGM2 (0.52) | ALDH1A1LMNACYP19A1TGM2MEN1 | |
| SCHEMBL24310716 | 0.84 | ALDH1A1 (0.68) | ALDH1A1LMNACYP19A1TGM2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2731932-B1 | AMINOMETHYL QUINOLONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-12-30 | — | — | EP | claimed |
| CN-103649053-A | Aminomethyl quinolone compounds | HOFFMANN LA ROCHE | 2014-03-19 | — | — | CN | claimed |
| US-8501732-B2 | Aminomethyl quinolone compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-08-06 | — | — | US | claimed |
| US-20130018043-A1 | AMINOMETHYL QUINOLONE COMPOUNDS | BILOTTA JOSEPH A (US) | 2013-01-17 | — | — | US | claimed |
| WO-2008073461-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | claimed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3760625-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| CN-111269221-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2023119210-A1 | NOVEL COMPOUND AS RIPK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 제일약품주식회사 | 2023-06-29 | — | — | WO | disclosed |
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-06-01 | — | — | US | disclosed |
| EP-3154964-B1 | TRIAZOLE MODIFIED COUMARIN AND BIPHENYL AMIDE-BASED HSP90 INHIBITORS | UNIV KANSAS (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-2173735-A1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| CN-101687844-A | Imidazole derivatives as CCR2 receptor antagonists | HOFFMANN LA ROCHE | 2010-03-31 | — | — | CN | disclosed |
| US-20090012063-A1 | Novel imidazole derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2009003861-A1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008073461-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018043-A1 | AMINOMETHYL QUINOLONE COMPOUNDS | MAP3K1, MAP3K11, MAP3K5 | ALDH1A1 3178/4885LMNA 2209/4885CYP19A1 1466/4885 |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | ALDH1A1 286/4885LMNA 2677/4885CYP19A1 135/4885 |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | ALDH1A1 1195/4885LMNA 94/4885CYP19A1 29/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | ALDH1A1 374/4885LMNA 2573/4885CYP19A1 227/4885 |
| US-20090012063-A1 | Novel imidazole derivatives | CCR2, CCR1, CCR3 | ALDH1A1 1556/4885LMNA 4708/4885CYP19A1 4490/4885 |
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | RIPK1, RIPK3, RIPK4 | ALDH1A1 4092/4885LMNA 2656/4885CYP19A1 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.